BioCentury
ARTICLE | Clinical News

Astellas/Vical CMV vaccine fails stem cell transplant trial

January 22, 2018 8:17 PM UTC

Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary and secondary endpoints in the Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients.

Vical sank $0.43 (23%) to $1.44 on Monday. The company told BioCentury it does not plan to develop ASP0113 independently if Astellas terminates its exclusive, worldwide license to the candidate, which the pharma obtained in 2011. Astellas declined to disclose its plans for ASP0113...